Clinical trial / 2005
In older adults with mild vitamin B12 deficiency, daily oral cyanocobalamin doses of 647 to 1032 mcg produced 80% to 90% of maximal methylmalonic acid reduction.
A randomized, parallel-group, double-blind, dose-finding trial evaluated the effects of 16 weeks of daily oral cyanocobalamin (2.5, 100, 250, 500, and 1000 mcg) in 120 older adults with mild vitamin B12 deficiency. Daily doses of 2.5, 100, 250, 500, and 1000 mcg were associated with mean plasma methylmalonic acid reductions of 16%, 16%, 23%, 33%, and 33%, respectively. Daily doses of 647 to 1032 mcg were associated with 80% to 90% of the estimated maximum reduction in plasma methylmalonic acid.
- Study type
- Randomized, parallel-group, double-blind, dose-finding trial
- Who was studied
- 120 older people with mild vitamin B12 deficiency
- What was measured
- Dose producing 80% to 90% of estimated maximal reduction in plasma methylmalonic acid
THE PAPER
Oral cyanocobalamin supplementation in older people with vitamin B12 deficiency: a dose-finding trial.
Eussen SJ, de Groot LC, Clarke R, Schneede J, Ueland PM, Hoefnagels WH, van Staveren WA. Arch Intern Med, 2005.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.